PuSH - Publication Server of Helmholtz Zentrum München: Modified vaccinia virus Ankara delivers a robust surrogate marker for immune monitoring to sarcoma cells even if cells are being exposed to chemotherapy and heat treatment.

Navigation

Home

Deutsch

Research

Advanced Search

Browse by ...

... Journal

... Publication Type

... Research Data

... Publication Year

Publication overview

Support & Contact

Contact persons

Help

Data protection

Tschöp-Lechner, K. ; Drexler, I. ; Hammer, D. ; Neumann, D. ; Pohla, H. ; Sutter, G.* ; Nößner, E. ; Issels, R.D.

Modified vaccinia virus Ankara delivers a robust surrogate marker for immune monitoring to sarcoma cells even if cells are being exposed to chemotherapy and heat treatment.

Int. J. Hyperthermia 28, 33-42 (2012)

DOI

PMC

Open Access Gold as soon as Publ. Version/Full Text is submitted to ZB.

Abstract
Metrics
Extra information

Purpose: Adding hyperthermia to chemotherapy improved the clinical outcome of patients with high risk soft tissue sarcoma. Further improvement might be possible if combined with vaccination strategies. As no sarcoma-associated antigens are known, the ecto

Altmetric

Additional Metrics?

[➜Log in]

Edit extra informations Login

Publication type Article: Journal article

Document type Scientific Article

Corresponding Author

Keywords Hyperthermia ; Immune Monitoring ; Mva ; Sarcoma ; Tumour Vaccine; CYTOTOXIC T-CELLS; MELANOMA-ASSOCIATED ANTIGEN; AUTOLOGOUS TUMOR-CELLS; DENDRITIC CELLS; IN-VITRO; METASTATIC MELANOMA; HUMAN TYROSINASE; TRIAL; HYPERTHERMIA; VACCINATION

ISSN (print) / ISBN 0265-6736

e-ISSN 1464-5157

Journal International Journal of Hyperthermia

Quellenangaben Volume: 28, Issue: 1, Pages: 33-42

Publisher Informa Healthcare

Non-patent literature Publications

Reviewing status Peer reviewed

Institute(s) Institute of Molecular Immunology (IMI)
Institute of Virology (VIRO)
CCG Tumor Therapy with Hyperthermia (IMI-KTH)